DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Event

2021 年 10 月 19 日 10:00 上午 - 2021 年 10 月 20 日 5:00 下午

(US Eastern Standard Time)

Horsham, PA 19044

DIA Canadian Annual Meeting

The Canadian Annual Meeting now includes a track for Pharmacovigilence and Risk Management Strategies!

Session 3 Track C: Post-Market Surveillance

Session Chair(s)

Marcia  Bailey, BSN, MHS, RN

Marcia Bailey, BSN, MHS, RN

Safety Evaluation and Risk Management Scientific Director, GSK, Canada

Caroline  Croteau, PhD, RPh

Caroline Croteau, PhD, RPh

Country Safety Lead, Pfizer Canada Inc, Canada

Deborah  Danoff, MD, FRCPC

Deborah Danoff, MD, FRCPC

Medical Evaluator, Health Canada, Canada

Post-market surveillance requires close collaboration between industry and the regulatory authorities. An essential aspect of post-market surveillance is adverse reaction reporting, a requirement that both industry and regulatory authorities have obligations towards. Industry is exploring innovative methods to gain additional information and facilitate risk mitigation for newer therapies. At the same time, Health Canada has reached out to industry to understand concerns related to proposed changes to the Reporting Adverse Reactions to Marketed Health Products - Guidance Document for Industry This session will explore approaches to post market surveillance from the perspectives of both industry and regulatory authorities. This will include the current revision process of the Guidance Document for Industry including comments received from stakeholders, as well as key changes being considered. Results from a pilot COVID-19 social listening program will also be presented.

Learning Objective : By the end of this session, participants should be able to:
  • Describe the extension of patient support programs to include both generics and brand name products
  • Outline how extra solicited reports / patient support programs can mitigate risk
  • Understand adverse reaction reporting requirements for industry
  • Identify the changes that are under consideration in the guidance document in response to stakeholder comments

Speaker(s)

Paul  Litowitz, MBA, RAC

Paul Litowitz, MBA, RAC

Manager, Public and Regulatory Affairs Outreach Section , Health Canada, Canada

Reporting Adverse Reactions to Marketed Health Products Guidance Document for Industry

Manfred  Hauben, MD, MPH

Manfred Hauben, MD, MPH

Senior Director Product Safety Surveillance and Reporting, Pfizer , United States

Pharmacovigilance Signal Detection and Information Monitoring for COVID-19 Vaccine Using Social Listening

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。